![](https://www.drugtargetreview.com/wp-content/uploads/shutterstock_2252983461-scaled.jpg)
Unleashing the potential of lab-grown recombinant polyclonal antibodies
In this Q&A, Sheila Keating, Vice President of Immunology at GigaGen, a Grifols company, explains how its developments in recombinant polyclonal antibody therapies are helping to build a pipeline of highly effective treatments for a wide range of …